European Journal of Health Economics

Papers
(The H4-Index of European Journal of Health Economics is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Education and medication use later in life and the role of intelligence87
Beyond 10-year lead-times in EQ-5D-5L: leveraging alternative lead-times in willingness-to-accept questions to capture preferences for worse-than-dead states and their implication69
Correction to: Geographic distribution of physicians in Portugal42
Pragmatic randomized controlled trial comparing a complex telemedicine-based intervention with usual care in patients with chronic conditions30
Psychometric properties and general population reference values for PROMIS Global Health in Hungary30
The hidden cost of sophistication: economic complexity and obesity26
Comparing the measurement properties of the EQ-5D-Y-3L, EQ-5D-Y-5L and CHU9D in children and adolescents: a measurement property study25
Cost-effectiveness of transcatheter aortic valve implantation in patients at low surgical risk in France: a model-based analysis of the Evolut LR trial25
Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries25
Patient-level cost analysis of subfertility pathways in the Dutch healthcare system24
Should Scotland provide genome-wide sequencing for the diagnosis of rare developmental disorders? A cost-effectiveness analysis22
Expensive today but cheaper tomorrow: lifetime costs of an active middle ear implant compared to alternative treatment options21
Workload and short sickness absences in a cohort of Finnish hospital employees21
Nothing about us, without us? A reflection on and call for involving children in the process of valuing child health21
Prescription opioids and economic hardship in France21
Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan20
Cost awareness among intensivists in their daily clinical practice: a prospective multicentre study20
Replay to: Comparison of EQ-5D-5 L and EORTC QLU-C10D utilities in gastric cancer patients19
Setting incentives right with long-term risk adjustment19
Primary care services and emergency department visits in blended fee-for-service and blended capitation models: evidence from Ontario, Canada19
From test to rest: evaluating socioeconomic differences along the COVID-19 care pathway in the Netherlands19
0.37266492843628